US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

0.2574

-0.0144-5.30%

Post-market: 0.26110.0037+1.44%16:29 EDT

Volume:821.48K

Turnover:213.86K

Market Cap:16.26M

PE:-0.16

High:0.2750

Open:0.2700

Low:0.2550

Close:0.2718

52wk High:3.05

52wk Low:0.2425

Shares:63.18M

Float Shares:56.90M

Volume Ratio:0.40

T/O Rate:1.44%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6597

EPS(LYR):-2.7356

ROE:-7446.11%

ROA:-110.67%

PB:-9.22

PE(LYR):-0.09

Loading ...

Overview Company News Filings

Medicus Pharma Advances SkinJect and Teverelix Amid Financing Gains and Going-Concern Risk

Medicus Pharma Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate

Benzinga Earnings

Medicus Pharma Q2 EPS USD -0.21

THOMSON REUTERS

Medicus Pharma Q2 Operating Expenses USD 11.5 Million

THOMSON REUTERS

Medicus Pharma FY26 Q2 Net Loss Widens 89.1% to $11.68 Million

Medicus Pharma Ltd Expected to Post a Loss of 13 Cents a Share - Earnings Preview

Medicus UK Unit Antev Names Faisal Mehmud CEO Effective Aug. 30

Medicus Pharma Appoints DR. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

THOMSON REUTERS

Press Release: Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom

Medicus Pharma - UAE Department of Health Grants Ind Authorization for Precision-E2 Phase 2a Study of Teverelix

THOMSON REUTERS

Medicus Pharma Wins UAE DOH IND Clearance for Teverelix Endometriosis Phase 2a Trial

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study

Medicus Pharma Wins FDA Clearance to Start SkinJect Registrational Gorlin Syndrome Trial

Medicus Pharma Receives FDA “Study May Proceed” Letter for Nda-Enabling Registrational Skinject® Study in Patients with Gorlin Syndrome

THOMSON REUTERS

Medicus Pharma Wins FDA Backing for Optimized Phase 2 Teverelix Study in Acute Urinary Retention

Medicus Pharma - Central Irb Approves Ant-2111-02 Protocol with Modifications Through June 18, 2027

THOMSON REUTERS

Medicus Pharma Receives Positive FDA Feedback and Central Irb Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

THOMSON REUTERS

Medicus Pharma - Phase 2 Study Ant-2111-02 to Evaluate Teverelix DP in Acute Urinary Retention

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/MDCX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":0.2574,"timestamp":1787601600000,"preClose":0.2718,"halted":0,"volume":821480,"hourTrading":{"tag":"盘后","latestPrice":0.2611,"preClose":0.2574,"latestTime":"16:29 EDT","volume":1590,"amount":408.556065,"timestamp":1787603375096,"change":0.0037,"changeRate":0.014375,"amplitude":0.021756},"delay":0,"changeRate":-0.052980132450331015,"floatShares":56901000,"shares":63180610,"eps":-1.659689,"marketStatus":"Post-Mkt","change":-0.0144,"latestTime":"08-24 16:42:07 EDT","open":0.27,"high":0.275,"low":0.255,"amount":213859,"amplitude":0.073584,"askPrice":0.29,"askSize":206,"bidPrice":0.2559,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-1.659689,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":0.2718,"preHourTrading":{"tag":"盘前","latestPrice":0.27,"preClose":0.2718,"latestTime":"09:21 EDT","volume":7422,"amount":2017.2405951,"timestamp":1787577687274,"change":-0.0018,"changeRate":-0.006623,"amplitude":0.036792},"postHourTrading":{"tag":"盘后","latestPrice":0.2611,"preClose":0.2574,"latestTime":"16:29 EDT","volume":1590,"amount":408.556065,"timestamp":1787603375096,"change":0.0037,"changeRate":0.014375,"amplitude":0.021756},"volumeRatio":0.401949},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":56901000,"roa":"-110.67%","roe":"-7446.11%","lyrEps":-2.735593,"volumeRatio":0.401949,"shares":63180610,"dividePrice":0,"high":0.275,"amplitude":0.073584,"preClose":0.2718,"low":0.255,"week52Low":0.2425,"pbRate":"-9.22","week52High":3.05,"institutionHeld":0,"latestPrice":0.2574,"committee":0.871491,"eps":-1.659689,"divideRate":0,"volume":821480,"delay":0,"ttmEps":-1.659689,"open":0.27,"prevYearClose":1.53,"prevWeekClose":0.2718,"prevMonthClose":0.2752,"prevQuarterClose":0.4463,"fiveDayClose":0.26,"twentyDayClose":0.3182,"sixtyDayClose":0.3293},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"MDCX","fiscalQuarterEnding":"2026/06","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2026-05-14","symbol":"MDCX","fiscalQuarterEnding":"2026/03","expectedEps":-0.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.31},{"market":"US","date":"2026-03-25","symbol":"MDCX","fiscalQuarterEnding":"2025/12","expectedEps":-0.32,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"post","actualEps":-0.82},{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"Post-Mkt","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1785297600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-08-21","current":-0.155511,"percent":0.899194,"low":-3.23298,"twenty":-2.211687,"median":-0.793282,"eighty":-0.354379,"high":-0.235266,"avg":-1.122787,"sd":0.953831,"marketCap":17197762},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-13","current":-0.709738,"twenty":-2.853549,"median":-1.933403,"eighty":-0.974021,"marketCap":25373688},{"date":"2026-02-20","current":-0.786136,"twenty":-2.850483,"median":-1.381324,"eighty":-0.961937,"marketCap":28104981},{"date":"2026-02-27","current":-0.97195,"twenty":-2.849812,"median":-1.344224,"eighty":-0.949581,"marketCap":34747976},{"date":"2026-03-06","current":-0.484474,"twenty":-2.849812,"median":-1.300152,"eighty":-0.949581,"marketCap":17320333},{"date":"2026-03-13","current":-0.412761,"twenty":-2.835443,"median":-1.263181,"eighty":-0.891018,"marketCap":14756541},{"date":"2026-03-20","current":-0.412761,"twenty":-2.825864,"median":-1.220048,"eighty":-0.847322,"marketCap":14756541},{"date":"2026-03-27","current":-0.387698,"twenty":-2.82079,"median":-1.201563,"eighty":-0.836077,"marketCap":18330934},{"date":"2026-04-02","current":-0.349652,"twenty":-2.811211,"median":-1.179996,"eighty":-0.820403,"marketCap":16532085},{"date":"2026-04-10","current":-0.367967,"twenty":-2.792337,"median":-1.125793,"eighty":-0.786136,"marketCap":17398052},{"date":"2026-04-17","current":-0.250001,"twenty":-2.775573,"median":-1.109135,"eighty":-0.744685,"marketCap":11820441},{"date":"2026-04-24","current":-0.276475,"twenty":-2.764797,"median":-1.099378,"eighty":-0.508201,"marketCap":13072156},{"date":"2026-05-01","current":-0.235266,"twenty":-2.75402,"median":-1.088841,"eighty":-0.417566,"marketCap":11123732},{"date":"2026-05-08","current":-0.277717,"twenty":-2.74923,"median":-1.069002,"eighty":-0.412761,"marketCap":13130880},{"date":"2026-05-15","current":-0.393186,"twenty":-2.733353,"median":-1.041354,"eighty":-0.401798,"marketCap":18590424},{"date":"2026-05-22","current":-0.308017,"twenty":-2.714637,"median":-1.024243,"eighty":-0.38811,"marketCap":15777036},{"date":"2026-05-29","current":-0.354651,"twenty":-2.703729,"median":-1.018593,"eighty":-0.376126,"marketCap":18165658},{"date":"2026-06-05","current":-0.402361,"twenty":-2.691755,"median":-0.976444,"eighty":-0.374724,"marketCap":20609444},{"date":"2026-06-12","current":-0.35842,"twenty":-2.672597,"median":-0.968141,"eighty":-0.372398,"marketCap":18358733},{"date":"2026-06-18","current":-0.378775,"twenty":-2.63428,"median":-0.962395,"eighty":-0.367967,"marketCap":19401342},{"date":"2026-06-26","current":-0.492235,"twenty":-2.63428,"median":-0.955088,"eighty":-0.371628,"marketCap":25212882},{"date":"2026-07-02","current":-0.442458,"twenty":-2.59471,"median":-0.94132,"eighty":-0.37203,"marketCap":22663265},{"date":"2026-07-10","current":-0.467347,"twenty":-2.543128,"median":-0.915037,"eighty":-0.3732,"marketCap":23938074},{"date":"2026-07-17","current":-0.449095,"twenty":-2.516028,"median":-0.871896,"eighty":-0.374395,"marketCap":23003214},{"date":"2026-07-24","current":-0.424981,"twenty":-2.511859,"median":-0.846653,"eighty":-0.374627,"marketCap":21768066},{"date":"2026-07-31","current":-0.290474,"twenty":-2.411802,"median":-0.843141,"eighty":-0.371929,"marketCap":14878433},{"date":"2026-08-07","current":-0.34025,"twenty":-2.326336,"median":-0.835949,"eighty":-0.363051,"marketCap":17428051},{"date":"2026-08-14","current":-0.353971,"twenty":-2.282561,"median":-0.821824,"eighty":-0.360424,"marketCap":20056990},{"date":"2026-08-21","current":-0.30351,"twenty":-2.211687,"median":-0.793282,"eighty":-0.354379,"marketCap":17197762}],"updateTime":1787590071951},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659186988","title":"Medicus Pharma Advances SkinJect and Teverelix Amid Financing Gains and Going-Concern Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659186988?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:37","pubTimestamp":1786574244,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd ( ($MDCX) ) has shared an update. Medicus Pharma reported second quarter 2026 results that reflected its evolution into a divers...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-advances-skinject-and-teverelix-amid-financing-gains-and-going-concern-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-advances-skinject-and-teverelix-amid-financing-gains-and-going-concern-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659918658","title":"Medicus Pharma Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659918658","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659918658?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:34","pubTimestamp":1786574083,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd reports results for the quarter ended June 30 - Earnings SummaryMedicus Pharma LtdMDCX.OQreported a quarterly adjusted loss of 21 cents per share for the quarter ended June 30, high","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4492BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659918525","title":"Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659918525","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659918525?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:02","pubTimestamp":1786572157,"startTime":"0","endTime":"0","summary":"Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.13) by 61.54 percent. This is a 51.16 percent increase over losses of $(0.43) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61162933/medicus-pharma-q2-eps-0-21-misses-0-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659854111","title":"Medicus Pharma Q2 EPS USD -0.21","url":"https://stock-news.laohu8.com/highlight/detail?id=2659854111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659854111?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:00","pubTimestamp":1786572023,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXZX85SN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659185419","title":"Medicus Pharma Q2 Operating Expenses USD 11.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659185419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659185419?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:00","pubTimestamp":1786572023,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXZX85SN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659424183","title":"Medicus Pharma FY26 Q2 Net Loss Widens 89.1% to $11.68 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659424183","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659424183?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:21","pubTimestamp":1786569697,"startTime":"0","endTime":"0","summary":"Medicus Pharma FY26 Q2 net loss widens 89.1% to $11.68 millionMedicus Pharma posted a Q2 net loss of USD 11.68 million, widening from USD 6.18 million a year earlier.Operating loss widened to USD 11.48 million as total operating expenses rose 90.8% to USD 11.48 million.General and administrative costs climbed 43.6% to USD 6.57 million; R&D spending more than doubled to USD 4.91 million.Cash and cash equivalents were USD 15.17 million at June 30, with USD 10.02 million of restricted cash and working capital of USD 6.14 million.FDA issued a “Study May Proceed” letter for SkinJect’s SKNJCT-005 Phase 2b registrational trial; UAE DOH authorized Teverelix PRECISION-E2 Phase 2a.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLcdLr7D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657290136","title":"Medicus Pharma Ltd Expected to Post a Loss of 13 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657290136","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657290136?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:35","pubTimestamp":1786138521,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd <MDCX.OQ> expected to post a loss of13cents a share - Earnings PreviewMedicus Pharma LtdMDCX.OQMDCX.Ois expected to  show no change in quarterly revenue when it reports  results on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375917","title":"Medicus UK Unit Antev Names Faisal Mehmud CEO Effective Aug. 30","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375917","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375917?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:30","pubTimestamp":1785756631,"startTime":"0","endTime":"0","summary":"Medicus UK unit Antev names Faisal Mehmud CEO effective Aug. 30Medicus’ UK subsidiary Antev named Faisal Mehmud CEO, effective Aug. 30, 2026.Mehmud keeps roles as Medicus chief medical officer, Antev ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL9Bf2Kx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014039.USD","BK4139","BCDF","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","MDCX","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014013.SGD","BK4585","SG9999014021.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375980","title":"Medicus Pharma Appoints DR. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375980","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375980?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:30","pubTimestamp":1785756600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA8KSWWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375165","title":"Press Release: Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375165","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375165?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:30","pubTimestamp":1785756600,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (\"Medicus\" or the \"Company\"), a biotech/life sciences company focused on advancing the clinical development programs ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4205","BCC","UBCP","BK4232","BK4104","BK4528","MRCP","BK4022","BK4233","MDCX","R","BK4567","BK4139","UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655363165","title":"Medicus Pharma - UAE Department of Health Grants Ind Authorization for Precision-E2 Phase 2a Study of Teverelix","url":"https://stock-news.laohu8.com/highlight/detail?id=2655363165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655363165?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:30","pubTimestamp":1785497426,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X0OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655363467","title":"Medicus Pharma Wins UAE DOH IND Clearance for Teverelix Endometriosis Phase 2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2655363467","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655363467?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:30","pubTimestamp":1785497424,"startTime":"0","endTime":"0","summary":"Medicus Pharma wins UAE DOH IND clearance for Teverelix endometriosis Phase 2a trialMedicus Pharma won UAE Department of Health IND clearance to start the PRECISION-E2 Phase 2a Teverelix study in mode","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL1jRj2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","MDCX","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","IE00BKPKM429.USD","BK4139","LU2095319765.USD","SG9999014021.USD","SG9999014039.USD","BCDF","SG9999014005.SGD","IE00B64PRP62.GBP","BK4112","SG9999014013.SGD","LU2210150020.SGD","BK4585","BK4588","LU0314104364.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655632143","title":"Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2655632143","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655632143?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:30","pubTimestamp":1785497400,"startTime":"0","endTime":"0","summary":"Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's healthPHILADELPHIA, July  31, 2026  (GLOBE NEWSWIRE) -- Medicus Phar","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/31/3336735/0/en/Medicus-Pharma-Receives-UAE-Department-of-Health-DOH-Authorization-to-proceed-with-Novel-Prospective-Genomics-Guided-Precision-Medicine-Study-Evaluating-Teverelix-in-Women-with-End.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU2237443895.HKD","BK4104","IE00B1BXHZ80.USD","LU2237443622.USD","LU2237443978.SGD","BK4567","UAE","IE00BFXG1179.USD","CMC","LU2746668461.USD","LU0149725797.USD","LU0267386448.USD","LU1363072403.SGD","BCC","BK4139","LU0882574139.USD","IE00BZ1G4Q59.USD","BK4006","LU2746668974.SGD","LU0170899867.USD","IE00BHPRN162.USD","LU0971096721.USD","LU2237443549.SGD","IE00BKVL7J92.USD","MDCX","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654322043","title":"Medicus Pharma gets FDA green light for SkinJect Phase 2b Gorlin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2654322043","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654322043?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:10","pubTimestamp":1785157848,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) announced the FDA has completed its safety review of the company’s Investigational New Drug application for SKNJCT-005 and is...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-gets-fda-green-light-for-skinject-phase-2b-gorlin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-gets-fda-green-light-for-skinject-phase-2b-gorlin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","MDCX","BK4139","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654301704","title":"Medicus Pharma Wins FDA Clearance to Start SkinJect Registrational Gorlin Syndrome Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654301704","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654301704?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:17","pubTimestamp":1785154645,"startTime":"0","endTime":"0","summary":"Medicus Pharma wins FDA clearance to start SkinJect registrational Gorlin syndrome trialMedicus received an FDA “study may proceed” letter, clearing its SKNJCT-005 Phase 2b registrational trial of Ski","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL6zgbh8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4585","BK4112","MDCX","LU2210149790.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","BCDF","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654501701","title":"Medicus Pharma Receives FDA “Study May Proceed” Letter for Nda-Enabling Registrational Skinject® Study in Patients with Gorlin Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2654501701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654501701?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:17","pubTimestamp":1785154620,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUARLLQZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449586","title":"Medicus Pharma Wins FDA Backing for Optimized Phase 2 Teverelix Study in Acute Urinary Retention","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449586","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449586?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201440,"startTime":"0","endTime":"0","summary":"Medicus Pharma wins FDA backing for optimized Phase 2 Teverelix study in acute urinary retentionMedicus received FDA written feedback backing an optimized Phase 2 Teverelix study in acute urinary rete","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL3PC0C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BCDF","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4588","SG9999014005.SGD","BK4139","SG9999014021.USD","LU0314104364.USD","LU2095319765.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014039.USD","NDAQ","BK4112","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651644934","title":"Medicus Pharma - Central Irb Approves Ant-2111-02 Protocol with Modifications Through June 18, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2651644934","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651644934?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUABKZ8WK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651544932","title":"Medicus Pharma Receives Positive FDA Feedback and Central Irb Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention","url":"https://stock-news.laohu8.com/highlight/detail?id=2651544932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651544932?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUABKZ8WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449367","title":"Medicus Pharma - Phase 2 Study Ant-2111-02 to Evaluate Teverelix DP in Acute Urinary Retention","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449367?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUABKZ8WK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":106,"code":"91000000","status":"200"}]}}